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Abstract
Background Differentiating heart failure from chronic obstructive pulmonary disease (COPD) in a patient presenting with 
breathlessness is difficult but may have implications for outcome. We investigated the prognostic impact of diagnoses of 
COPD and/or heart failure in consecutive patients presenting to a secondary care clinic with breathlessness.
Methods In patients with left ventricular systolic dysfunction (LVSD) by visual estimation, N-terminal pro B-type natriuretic 
peptide (NTproBNP) levels and spirometry were evaluated (N = 4986). Heart failure was defined as either LVSD worse than 
mild (heart failure with reduced ejection fraction) or LVSD mild or better and raised NTproBNP levels (> 400 ng/L) (heart 
failure with normal ejection fraction). COPD was defined as forced expiratory volume in 1 s  (FEV1) to forced vital capacity 
(FVC) ratio < 0.7. The primary outcome was all-cause mortality.
Results 1764 (35%) patients had heart failure alone, 585 (12%) had COPD alone, 1751 (35%) had heart failure and COPD, 
and 886 (18%) had neither. Compared to patients with neither diagnosis, those with COPD alone [hazard ratio (HR) = 1.84 
95% confidence interval (CI) 1.40–2.43], heart failure alone [HR = 4.40 (95% CI 3.54–5.46)] or heart failure and COPD 
[HR = 5.44 (95% CI 4.39–6.75)] had a greater risk of death. COPD was not associated with increased risk of death in patients 
with heart failure on a multivariable analysis.
Conclusion While COPD is associated with increased risk of death compared to patients with neither heart failure nor COPD, 
it has a negligible impact on prognosis amongst patients with heart failure.
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Introduction
Breathlessness is common. Separating heart failure from 
chronic obstructive airways disease (COPD), both or nei-
ther can be difficult due to similarity in symptomatology 
and shared risk factors, such as increasing age and smok-
ing history. However, the distinction is important: there are 
numerous drug and device therapies that can prolong life 
in patients with heart failure and reduced ejection fraction 
(HeFREF) [1], but there is little evidence that commonly 
used treatments of COPD affect mortality [2]. In addition, 
patients with heart failure who are also diagnosed with 
COPD often receive suboptimal treatment, as they are less 
likely to be prescribed beta-blockers due to concerns about 
bronchoconstriction [3].
The ratio of forced expiratory volume in 1 s  (FEV1) to 
forced vital capacity (FVC) below 0.7 indicates obstructive 
pulmonary disease [4], and many patients with heart fail-
ure also have obstructive spirometry [5, 6]. Estimates of the 
prevalence of COPD amongst patients with heart failure vary 
between 8 and 52% depending on the definition of COPD 
[7, 8], but the impact of a co-diagnosis of COPD and heart 
failure is not clear.
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The European Society of Cardiology heart failure 
guidelines state that the presence of COPD (regardless 
of the definition) is associated with worse prognosis in 
patients with HeFREF. However, numerous studies inves-
tigating the effect of COPD on outcome in patients with 
heart failure have been inconsistent [6, 9–22]. Studies that 
have reported increased mortality amongst patients with 
heart failure and COPD compared with either diagnosis 
alone have either come from highly selected trial popula-
tions of patients with HeFREF [9, 15, 19], patients admit-
ted with acute heart failure [6, 11, 16], or have involved 
only short-term follow-up [10, 12, 20]. Up to half of 
patients with heart failure have a normal ejection fraction 
(HeFNEF) [23], but the prognostic significance of COPD 
amongst outpatients with HeFNEF has, so far, only been 
assessed in a small number of patients [22].
Reliable data on the long-term impact of a diagnosis of 
COPD on outcome in “real-world” outpatients with heart 
failure is scarce. We therefore assessed the impact of a diag-
nosis of COPD and/or heart failure on long-term mortality 
in a large cohort of consecutive ambulatory patients with 
breathlessness referred to a secondary care clinic with sus-
pected heart failure.
Methods
Setting, study design and patients
Between September 2000 and October 2016, all clinical, 
demographic, biochemical and echocardiographic data on 
consecutive patients referred from primary or secondary 
care to a community heart failure clinic serving a local pop-
ulation of about 500,000 people were recorded on a secure 
database (Hull LifeLab). Patients were followed-up until 1st 
November 2016. All subjects gave their written informed 
consent for their data to be used. The study conforms to the 
principles outlined in the Declaration of Helsinki and was 
approved by relevant ethical bodies.
Definitions and outcome
Heart failure was defined as the presence of signs and symp-
toms of the disease and either left ventricular dysfunction 
(LVSD) worse than mild—HeFREF; or LVSD mild or bet-
ter and N-terminal peptide of pro B-type natriuretic peptide 
(NTproBNP) level > 400 ng/L—HeFNEF [24]. Spirometry 
was performed routinely on all patients at baseline by trained 
nursing staff. COPD was defined as  FEV1:FVC < 0.7 as 
suggested by the GOLD criteria [4]. The primary outcome 
was all-cause mortality.
Statistical analysis
Categorical data are presented as number and percent-
ages, normally distributed continuous data are presented 
as mean ± standard deviation (SD) and non-normally dis-
tributed variables are presented as median and interquar-
tile range (IQR).
The relationship between  FEV1:FVC and other vari-
ables was assessed by Pearson’s correlation coefficient 
and linear regression. Variables associated with COPD 
as a categorical variable  (FEV1:FVC < 0.7) were assessed 
using logistic regression. Only variables with P < 0.1 (an 
arbitrary threshold) in univariable analysis were included 
in multivariable models. Log-transformed NTproBNP was 
used.
Patients with were divided into groups: heart failure 
alone; COPD alone; heart failure and COPD; and neither 
diagnosis. Patients with heart failure were sub-divided into 
those with HeFREF or HeFNEF. Chi-squared tests were 
used to compare categorical variables and one-way analy-
sis of variance (ANOVA) to compare continuous variables 
across the groups. Assumptions of ANOVA (normality of 
residuals and equal variance) were checked. Kruskal–Wal-
lis test was used to compare non-normally distributed con-
tinuous variables across quartiles and groups.
Associations between variables and outcome were 
assessed with Cox regression. Proportionality of hazards 
was checked by residual plotting. Univariable analysis 
was conducted using all variables in the dataset: variables 
with P > 0.1 in univariable analysis or with more than 10% 
missing values (an arbitrary threshold) were not included 
in the multivariable analyses. Kaplan–Meier curves were 
used to demonstrate outcome by group.
All statistical analyses were carried out using the SPSS 
24 software package with the two-tailed level of statistical 
significance set at P < 0.05.
Results
Of 4986 patients, 1764 (35%) had heart failure alone, 585 
(12%) had COPD alone, 1751 (35%) had both heart failure 
and COPD, and 886 (18%) had neither condition (Table 1). 
Of the 3515 total patients with heart failure, 2329 had 
HeFREF and 1186 had HeFNEF. The prevalence of COPD 
reported in the medical record (10% for HeFREF; 10% 
HeFNEF) was far lower than the prevalence of COPD by 
spirometry (49% for HeFREF; 51% for HeFNEF), but was 
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similar between the groups (P = 0.20) (Table 2) (Supple-
mentary Fig. 1).
Patient characteristics
Patients with COPD alone had similar NTproBNP levels 
and symptom severity but were older than patients with 
neither heart failure nor COPD. Atrial fibrillation was far 
less common in patients with COPD alone than in those 
with heart failure alone, heart failure and COPD or neither 
condition.
Patients with heart failure alone were similar in their 
age and smoking history but had more severe symptoms 
than patients with COPD alone. Patients with heart failure 
and COPD had similar symptom severity and rate of loop 
diuretic prescription but were older, had higher NTproBNP 
Table 1  Patient characteristics: all patients
Continuous data are presented as mean (± standard deviation) or median (interquartile range), categorical data are presented as N (percentage)
N number; COPD chronic obstructive pulmonary disease; BMI body mass index; SR sinus rhythm; IHD ischaemic heart disease; NYHA New 
York Heart Association; NTproBNP N-terminal B-type natriuretic peptide; eGFR estimated glomerular filtration rate; FEV1 forced expiratory 
volume in one second; FVC forced vital capacity; MRA mineralocorticoid receptor antagonist; ACEI angiotensin converting enzyme inhibitor; 
ARB angiotensin receptor blocker; βB beta-blocker; LVSD left ventricular systolic dysfunction; HeFNEF heart failure with normal ejection frac-
tion
Variable Missing All patients Heart failure COPD Heart failure and COPD Neither heart 
failure nor 
COPD
P
N = 4986 N = 1764 N = 586 N = 1750 N = 886
Demographics
 Age (years) 0 71 (± 11) 71 (± 12) 71 (± 10) 75 (± 10) 66 (± 12) < 0.001
 Sex (male)—N (%) 0 3068 (62) 1197 (68) 273 (47) 1139 (65) 459 (52) < 0.001
 BMI (kg/m2) 17 28.7 (± 6.0) 29.1 (± 6.1) 29.2 (± 5.6) 27.4 (± 5.7) 30.1 (± 6.2) < 0.001
 SR [N (%)] 80 3562 (71) 1087 (63) 559 (96) 1060 (62) 3562 (73) < 0.001
 Diabetes [N (%)] 308 970 (20) 407 (24) 80 (15) 334 (21) 149 (18) < 0.001
 IHD [N (%)] 31 2259 (45) 912 (52) 151 (26) 935 (54) 261 (30) < 0.001
 Documented COPD 
in medical records 
[N (%)]
31 478 (10) 118 (7) 86 (15) 223 (13) 51 (6) < 0.001
 Never smoked [N (%)] 319 1421 (30) 536 (33) 158 (29) 383 (24) 344 (41) < 0.001
Symptoms
 NYHA Class III/IV 
[N (%)]
245 1344 (28) 537 (31) 90 (17) 617 (36) 100 (14) < 0.001
Blood results
 NTproBNP [ng/L] 461 723 (179–2045) 1319 (656–2821) 140 (73–228) 1590 (742–3309) 113 (57–203) –
 Haemoglobin [g/dL] 395 13.5 (12.3–14.5) 13.4 (12.1–14.5) 13.8 (12.9–14.7) 13.2 (12.0–14.3) 13.9 (13.0–14.9) < 0.001
 eGFR [mL/
min/1.73 m2]
346 62 (48–77) 59 (44–74) 71 (58–83) 56 (42–70) 74 (62–87) < 0.001
 Albumin [g/L] 341 38 (36–40) 38 (35–40) 39 (37–40) 37 (35–39) 39 (37–41) < 0.001
Spirometry
 FEV1 [L] 0 1.76 (± 0.81) 1.96 (± 0.76) 1.51 (± 0.72) 1.38 (± 0.60) 2.30 (± 0.87) < 0.001
 FVC [L] 0 2.58 (± 1.00) 2.46 (± 0.95) 2.78 (± 1.07) 2.49 (± 0.95) 2.87 (± 1.09) < 0.001
 FEV1:FVC 0 0.69 (± 0.16) 0.80 (0.09) 0.54 (± 0.13) 0.56 (± 0.12) 0.80 (± 0.09) –
Medications
 Loop diuretic [N (%)] 107 2932 (60) 1240 (71) 191 (34) 1265 (73) 236 (28) < 0.001
 MRA [N (%)] 107 886 (18) 443 (25) 25 (5) 382 (22) 36 (4) < 0.001
 ACEI or ARB [N (%)] 107 3142 (63) 1266 (73) 248 (44) 1250 (72) 378 (45) < 0.001
 βB [N (%)] 107 2503 (50) 1090 (63) 170 (30) 948 (55) 295 (35) < 0.001
Echocardiography
 Severe LVSD [N (%)] 0 411 (8) 207 (12) 0 (0) 204 (12) 0 (0) –
 HeFNEF [N (%)] 0 1186 (24) 583 (33) 0 (0) 603 (34) 0 (0) –
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levels, and were less likely to be prescribed a beta-blocker 
than patients with heart failure alone.
Patients with heart failure regardless of the presence of 
COPD were more likely to be male, have ischaemic heart 
disease and had a lower estimated glomerular filtration rate 
(eGFR) than patients without heart failure (Table 1).
Compared to patients with HeFREF, patients with HeF-
NEF were older, more likely to be female, less likely to 
have ischaemic heart disease (IHD), less likely to have 
severe symptoms, less likely to be prescribed loop diuretic 
and had lower NTproBNP levels (Table 2).
Table 2  Patient characteristics: all patients with heart failure (N = 3515)
Continuous data are presented as mean (± standard deviation) or median (interquartile range), categorical data are presented as N (percentage)
N number; HeFREF heart failure with a reduced ejection fraction; HeFNEF heart failure with normal ejection fraction; COPD chronic obstruc-
tive pulmonary disease; BMI body mass index; SR sinus rhythm; IHD ischaemic heart disease; NYHA New York Heart Association; NTproBNP 
N-terminal B-type natriuretic peptide; eGFR estimated glomerular filtration rate; FEV1:FVC ratio of forced expiratory volume in one second 
to forced vital capacity; MRA mineralocorticoid receptor antagonist; ACEI angiotensin converting enzyme inhibitor; ARB angiotensin receptor 
blocker; βB beta-blocker; LVSD left ventricular systolic dysfunction; LVEF left ventricular ejection fraction
Variable Missing All patients with 
heart failure
HeFREF HeFNEF HeFREF and 
COPD
HeFNEF and 
COPD
P
N = 3515 N = 1181 N = 583 N = 1148 N = 603
Demographics
 Age (years) 0 73 (± 11) 69 (± 12) 75 (± 10) 73 (± 10) 77 (± 8) < 0.001
 Sex (male)—N (%) 0 2336 (67) 871 (74) 326 (56) 851 (74) 288 (48) < 0.001
 BMI [kg/m2] 13 28.3 (± 5.9) 28.7 (± 5.7) 29.9 (± 6.8) 26.9 (± 5.2) 28.4 (± 6.3) < 0.001
 SR [N (%)] 65 2148 (62) 809 (70) 278 (48) 754 (67) 307 (52) < 0.001
 Diabetes [N (%)] 206 742 (22) 278 (25) 129 (24) 216 (20) 119 (21) 0.07
 IHD [N (%)] 12 1848 (53) 713 (61) 199 (35) 735 (64) 201 (33) < 0.001
 Documented 
COPD in medi-
cal records [N 
(%)]
12 341 (10) 74 (6) 44 (8) 149 (13) 74 (12) < 0.001
 Never smoked [N 
(%)]
237 919 (28) 332 (30) 204 (37) 215 (20) 168 (30) < 0.001
Symptoms
 NYHA Class III/
IV [N (%)]
59 1154 (33) 373 (33) 164 (28) 424 (38) 193 (33) < 0.001
Blood results
 NTproBNP (ng/L) 461 1421 (695–3109) 1444 (536–3486) 1192 (737–2241) 1825 (708–4013) 1328 (773–2542) < 0.001
 Haemoglobin (g/
dL)
294 13.3 (12.1–14.4) 13.6 (12.3–14.7) 13.1 (11.8–14.2) 13.3 (12.2–14.4) 12.9 (11.7–14.2) < 0.001
 eGFR (mL/
min/1.73 m2)
287 58 (43–72) 59 (46–74) 59 (43–74) 56 (43–70) 56 (41–69) < 0.001
 Albumin (g/L) 281 37 (35–40) 38 (35–40) 37 (35–39) 37 (35–40) 37 (34–39) < 0.001
Spirometry
 FEV1:FVC 0 0.68 (± 0.16) 0.80 (± 0.10) 0.80 (± 0.08) 0.56 (± 0.12) 0.56 (± 0.11) < 0.001
Medications
 Loop diuretic [N 
(%)]
37 2505 (72) 872 (75) 368 (64) 857 (75) 408 (68) < 0.001
 MRA [N (%)] 37 825 (24) 371 (32) 72 (13) 309 (27) 73 (27) < 0.001
 ACEI or ARB [N 
(%)]
37 2517 (72) 906 (78) 360 (62) 890 (78) 361 (61) < 0.001
 βB [N (%)] 37 2039 (59) 744 (64) 346 (60) 639 (56) 310 (52) < 0.001
Echocardiography
 Severe LVSD [N 
(%)]
0 916 (26) 457 (39) 0 (0) 459 (40) 0 (0) –
 LVEF by 
Simpsons (%)
1511 38.2 (± 12.6) 32.8 (± 8.0) 54.6 (± 6.7) 32.4 (± 8.2) 55.8 (± 7.64) –
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Associations with  FEV1:FVC < 0.7
On univariable analysis, there were weak positive cor-
relations between  FEV1:FVC ratio and body mass index 
(BMI), haemoglobin, eGFR and albumin; there were 
weak negative correlations between  FEV1:FVC ratio and 
age and NTproBNP (Supplementary Fig. 2). Of these, 
only age (β coefficient = − 0.14; t-statistic = − 7.8) and 
BMI (β = 0.10; t = 6.4) correlated with  FEV1:FVC on 
multivariable analysis (data not shown).
Outcome for all patients
During a median follow-up of 1825 days (IQR 802–1825), 
1551 patients died. Decreasing  FEV1:FVC as a continu-
ous variable and COPD as a categorical variable were 
associated with an increased risk of mortality in all 
patients, but not after adjustment for other variables such 
as age, NTproBNP, eGFR and NYHA class (Supplemen-
tary Table 1).
Patients with COPD alone were nearly twice as likely 
to die as patients with neither condition and patients with 
heart failure regardless of the presence of COPD were 
4–5 times more likely to die than patients with neither 
condition (Fig. 1).
Outcome for patients with heart failure
Amongst all patients with heart failure, during a median 
follow-up of 1534 days (IQR 572–1825), 1347 patients 
died. Decreasing  FEV1:FVC as a continuous variable and 
COPD as a categorical variable were associated with poor 
prognosis on univariable analysis. The presence of COPD 
was associated with poor prognosis on univariable analysis 
amongst patients with HeFREF but not amongst patients 
with HeFNEF (Fig. 2). Neither  FEV1:FVC as a continuous 
variable nor COPD as a categorical variable were associated 
with outcome after adjustment for other variables (Supple-
mentary Table 2).
Discussion
We have found that approximately half of patients with heart 
failure seen in a secondary care clinic have COPD (defined 
as  FEV1:FVC < 0.7). Compared to patients with neither heart 
failure nor COPD, those with COPD alone were at a higher 
risk of death, but those with heart failure had a far greater 
risk of mortality regardless of the presence of COPD.
The effect of a COPD diagnosis on heart failure
The diagnosis of COPD in a patient with heart fail-
ure (regardless of phenotype) has a negligible impact on 
Fig. 1  Survival curves for patients with heart failure, COPD, both or neither. Kaplan–Meier curves for 5-year mortality for patients with heart 
failure, COPD, both or neither. Abbreviations used: COPD chronic obstructive pulmonary disease. No number
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outcome. This runs counter to the assertion in the current 
European Society of Cardiology heart failure guidelines that, 
regardless of definition, COPD is associated with worse out-
come in patients with HeFREF [1].
Of all the studies that have demonstrated a significant 
association between the presence of COPD and increased 
risk of adverse outcome in patients with heart failure [6, 
9–12, 15, 16, 18–20, 22] only three defined COPD using 
spirometry and heart failure using echocardiography or 
natriuretic peptide levels [6, 20, 22]; of these three studies, 
only one adjusted for natriuretic peptide levels and found an 
association between COPD and all-cause mortality or car-
diovascular hospitalisation, but in a study of only 71 patients 
with HeFNEF [22]. Natriuretic peptide levels are powerful 
prognostic markers in patients with heart failure and may 
also be useful prognostic biomarkers in patients with COPD 
[25, 26]. Our results suggest that in patients with heart fail-
ure, it is high natriuretic peptide levels (a marker of heart 
failure severity), not the presence of COPD, which increases 
the risk of adverse outcome.
However, the diagnosis of COPD in a patient with 
heart failure may have important implications for manage-
ment. We found that the prevalence of COPD identified by 
abnormal spirometry is higher amongst patients with heart 
failure than recorded in the medical notes: COPD may be 
missed when breathlessness is attributed to the heart failure 
diagnosis. Registry data suggest that most patients with 
heart failure and COPD have the latter diagnosis confirmed 
without spirometry [27]. Indeed, most studies claiming to 
investigate the impact of COPD on outcome in patients with 
heart failure do not use spirometry to define COPD [9–11, 
14–16, 19]. Under-diagnosis of COPD amongst patients with 
heart failure may be common.
Bronchodilators can improve symptoms of breathless-
ness in patients with COPD [28], but are unlikely to be pre-
scribed in the absence of a diagnosis. There may be many 
patients with heart failure and undiagnosed COPD who are 
not receiving potentially symptom-relieving treatment.
An alternative explanation for the prevalence of COPD 
in our cohort is that heart failure may act as a mimic of 
COPD [5], possibly due to alveolar and pulmonary intersti-
tial oedema compressing small airways [25, 29]. Medical 
treatment of heart failure can correct abnormal spirometry 
in approximately 50% of patients with heart failure and 
‘COPD’ after 6 months [6], and optimising heart failure 
medications and diuretic dose according to invasively meas-
ured pulmonary artery pressure can reduce the risk of admis-
sion with respiratory illness [30]. As some of our cohort 
were new referrals and naïve to treatment, it is possible that a 
proportion of patients with “heart failure and COPD” merely 
had more severe heart failure rather than concurrent pulmo-
nary disease. However, it is important to note, regardless 
Fig. 2  Survival curves for patients with either HeFREF or HeFNEF 
with or without COPD. Kaplan–Meier curves for 5-year mortality 
for patients with heart failure with or without COPD. Abbreviations 
used: COPD chronic obstructive pulmonary disease; HeFNEF heart 
failure with normal ejection fraction; HeFREF heart failure with 
reduced ejection fraction; No number
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of whether obstructive spirometry  (FEV1:FVC < 0.7) repre-
sents ‘true COPD’ or just more severe heart failure, it had 
no effect on mortality.
The effect of a heart failure diagnosis on COPD
We found that a co-diagnosis of COPD and heart failure is 
far worse than having COPD alone. Many patients with heart 
failure have obstructive spirometry but the opposite may also 
be true: symptoms of heart failure such as breathlessness 
and peripheral oedema may be misinterpreted as COPD [31, 
32], particularly if the diagnosis of COPD is established: 
there may be cases of undiagnosed heart failure amongst 
patients with COPD [33]. This is a much more important 
situation than missing COPD in a patient with heart failure 
given the potent effects of medical therapy for patients with 
HeFREF [1].
Cardiovascular death is common amongst patients with 
COPD [34–39), and beta-blockers might reduce the risk of 
mortality amongst patients with COPD [39]. Whether other 
treatments that target cardiovascular risk (such as spirono-
lactone) can improve outcome in patients with COPD (and 
not heart failure) is unknown. Screening patients with COPD 
for heart failure using natriuretic peptides could identify 
those at greater risk of adverse outcome, and should be con-
sidered if there is any doubt that a patient’s symptoms are 
due to COPD alone.
Study limitations
The limitations of retrospective analyses apply to our study 
and confounding factors cannot be excluded. Our data rep-
resent a snapshot of a single time point and no conclusions 
can be drawn on the importance of changing spirometry or 
the effect of heart failure treatment on spirometry amongst 
patients with heart failure over time. Our data did not include 
reversibility studies as part of the spirometry, nor did we 
have data on hospitalisation rates.
Patients in whom COPD was the obvious cause of their 
symptoms are unlikely to have been referred to a heart fail-
ure service. The patients in our study with COPD alone are 
likely to be those with relatively mild disease and might 
thus not be truly representative of the ‘real-world’ COPD 
population. The role of our clinic is to identify and treat 
patients with heart failure, not identifying the specific 
underlying cause of breathlessness. For that reason we are 
unable to comment on the cause of breathlessness in the 
sub-group of patients with neither heart failure nor COPD 
(N = 886), although it is interesting to note that the average 
body mass index of patients in this group was higher than 
that of patients with heart failure and/or COPD (Table 1) and 
meets the National Institute of Clinical Excellence (NICE) 
diagnostic criteria for obesity [40].
Conclusions
The symptoms of heart failure and COPD overlap. Both 
carry an adverse prognosis. In patients with COPD, a coin-
cident diagnosis of heart failure greatly worsens prognosis, 
but an additional diagnosis of COPD in patients with heart 
failure does not affect outcome.
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